Up next

Autoplay

Carbozantinib demonstrates disease control in advanced adrenocortical carcinoma

2 Views • 06/15/23
Share
Embed
administrator
administrator
Subscribers
0

Matthew Campbell, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on an Phase II study (NCT03370718) exploring the role of carbozantinib, a tyrosine kinase inhibitor, in adrenocortical carcinoma (ACC) management. 18 patients were enrolled with advanced ACC, with the primary endpoint being progression-free survival (PFS) at 4 months (PFS4). The median follow-up was 19.4 months and the PFS4 was 72%, median PFS was 7.2 months. 16 patients had restaging with ORR including 2 partial response, 12 stable disease, and 2 progressive disease as best response; disease control rate was 78%. The median PFS was 7.2 months and median OS was 23.9 months. Overall, cabozantinib was shown to be able to provide sustained disease control in patients with advanced ACC and a manageable safety profile in the majority of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay